SpringWorks Therapeutics Reports Third Quarter 2022
– Presented Positive Data from Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Progressing Desmoid Tumors at the European Society for...
Stay updated with breaking news from Loss Attributable. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
– Presented Positive Data from Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Progressing Desmoid Tumors at the European Society for...
Second Quarter Revenue was $875.2 Million; Operating Loss was $1.75 BillionOperating Loss was $53.7 Million Before Impact of Non-Cash Goodwill Wri...
Third-Quarter 2022 Financial Results Revenues of $942 Million GAAP Net Loss Attributable to Bausch + Lomb Corporation of $18 Million Adjusted EBITDA...
Third-Quarter 2022 Financial Results Revenues of $942 Million GAAP Net Loss Attributable to Bausch + Lomb Corporation of $18 Million Adjusted EBITDA...
Highlights: Q3 2022 consolidated revenues of $840.1 million increased 12.3% over Q3 2021 primarily due to increased lift truck prices and parts volumes across...